INTRODUCTION
A promising approach to the development of novel subunit vaccines is antigen (Ag) delivery to dendritic cell (DC) subsets, which has key roles in the induction of adaptive immunity. Such vaccines could build on the knowledge of the properties of diverse DC subsets, defined according to their ontogenic origin, phenotype, and functions in different tissues. In the mouse spleen, three major DC subsets have been identified: (i) CD11c þ B220 þ BST-2 (bone marrow stromal cell Ag-2, CD317) þ plasmacytoid DCs (pDCs), specialized in the production of type-I interferons (IFNs); (ii) CD11c þ CD11b À CD8 a þ DCs, with the robust ability to take up dead cells, crosspresent the derived Ags, and trigger T cells via interleukin (IL)-12p70 secretion; and (iii) CD11c þ CD11b þ CD8 a À DCs, considered as potent inducers of major histocompatibility complex (MHC)-II-restricted T cells. 1 In mouse skin, in addition to the resident DCs of the lymph nodes, the epidermisderived CD205 (DEC205) hi 
CD11b
À DCs are present and can migrate to the alveolar lumen or to lymph nodes. CD11c int CD11b À BST-2 þ pDCs are detectable in the lung parenchyma and produce IFN-a upon Toll-like receptor (TLR) triggering. 3 Identification of human equivalents of mouse DC subsets represents an active field of investigation, leading to translation of knowledge generated in mice to humans to develop efficient vaccines based on Ag delivery to DCs.
The magnitude of the adaptive immunity and differentiation of CD4 þ T cells into T-helper (Th)1, Th2, or Th17 cells are 1 dictated by DC subsets. 4 Thus, mobilization of different DC populations by direct in vivo targeting of their surface receptors represents a promising strategy for the development of wellcontrolled immunization schemes. 5 This strategy has been pioneered by Steinman and Nussenzweig, who used Ag coupling to Abs to target receptors on DC surfaces. 6, 7 Although it is largely established that DCs translate information from different surface receptors into an activation program that orients Th cell differentiation, the complete set of rules governing functions of DC subsets is not yet understood. Therefore, it remains difficult to predict which DC subsets/DC surface receptors are the most appropriate to target for optimizing protective immunity against a given pathogen. Thus, comparison of the properties of various DC subsets on the generation of specific adaptive responses may help to identify the most appropriate DC subsets likely able to confer the most protective immunity. In this respect, the strategy of directed Ag delivery to DCs remains limited by the need for tedious individual chemical coupling or genetic fusion of the immunogen of interest to each individual monoclonal antibody (mAb), specific to any of the numerous DC surface receptors.
Here, we elaborated a versatile system enabling a combinatorial approach to identify appropriate receptor(s) for immunogen delivery into DCs. The strategy relies on genetic fusion of Ags to streptavidin (SA). The resulting Ag-SA tetramers can then be complexed in a combinatorial manner to a variety of biotin (biot)-conjugated mAbs chosen from a large panel of available mAbs specific for diverse DC surface receptors. This yields an inherent flexibility of choice in receptor targeting.
This system was applied to the development of a vaccine strategy against tuberculosis (TB), the major global infectious disease. The only vaccine currently in use against Mycobacterium tuberculosis is the live attenuated M. bovis BCG (Bacillus Calmette-Guérin), which cannot be used for booster immunization and does not confer long-lasting protection. 8 Among the most promising M. tuberculosis immunogens are the low-molecular weight proteins of the 6-kDa Early Secreted Antigenic Target (ESAT-6) protein family (ESX), 9 which are secreted by the type-VII secretion system and are known for their marked immunogenicity and protective potential in ethnically different human populations. Moreover, the presence of T-cell effectors specific to such proteins directly correlates to the natural protection in humans. 10, 11 We used here the DC-targeting strategy for selecting the most appropriate DC subsets or DC surface receptors for efficient capture/endocytosis/presentation of ESX Ags by MHC molecules in vivo and induction of protective T-cell responses. Directing the TB10.4 ESX Ag to airway CD205 þ cells then enabled induction of mucosal T-cell responses and protection against M. tuberculosis.
RESULTS

Mycobacterial ESX-SA fusion proteins
The complete sequences of mycobacterial ESX Ags ESAT-6 (ESX A), CFP-10 (ESX B), or TB10.4 (ESX H) were fused to the N terminus of the tetramerization core (residues 13-139) of SA. Soluble Ag-SA tetramers were produced and purified close to homogeneity (Figure 1a) as described previously. 12 The capacity of Ag-SA fusions to assemble into tetramers was preserved, which enabled their strong binding to biot-mAbs because of the high (K d B1 Â 10 À 15 M) affinity of the tetrameric SA for biot. 13 Ab-mediated binding of ESX-SA to DC surface receptors promotes Ag endocytosis
We evaluated the binding of ESAT-6-SA tetramers to DCs through biot-mAbs specific to various DC surface receptors. Conventional bone marrow (BM)-DCs were pre-incubated at 41C with biot-mAbs specific for CD11b or CD11c b 2 -integrins, or for MHC-II or DCIR-2 C-type lectins before the addition of ESAT-6-SA. As detected by anti-ESAT-6 mAb, the ESAT-6-SA displayed a marked binding to the surface of biot-mAb-treated DCs compared to cells pre-incubated with biot-control immunoglobulin G (IgG) (Figure 1b) . After 3 h incubation at 371C, the ESAT-6-specific surface fluorescence intensity was substantially reduced. This suggested that ESAT-6 was endocytosed by the targeted DCs. pBM-DCs (Figure 1b , right) or lung DCs (Supplementary Figure S1 online) pre-incubated with biot-anti-BST-2 or biot-anti-CD205 mAb, respectively, and then with ESAT-6-SA also showed binding of ESAT-6 at 41C, followed by its internalization at 371C. Therefore, ESAT-6-SA was delivered specifically to DC surface receptors by the selected biot-mAbs and endocytosed via CD11b or CD11c, DCIR-2, MHC-II, BST-2, or CD205.
Delivery of ESX Ags into the MHC-II pathway
We investigated the capacity of different Ag-presenting cells to which ESX Ag-SA were delivered via CD11b, CD11c, MHC-II, or BST-2 to present Ag-derived epitopes to specific T cells. BMDCs pre-incubated with biot-anti-CD11b, -CD11c or -MHC-II, and then with various concentrations of ESAT-6-SA, were able to present ESAT-6 to the I-A b -restricted, ESAT-6:1-20-specific NB11 T-cell hybridoma or to polyclonal anti-ESAT-6 T cells from M. tuberculosis-infected mice (Figure 1c ). pBM-DCs or BM-Mf, to which ESAT-6-SA was delivered, respectively, via BST-2 or CD11b, were able to stimulate NB11 hybridoma cells (Figure 1d ). BM-DCs (H-2 d ), to which TB10.4-SA was delivered via CD11b or MHC-II, also presented TB10.4 ( Figure 1e ) to the I-A d -restricted, TB10.4:74-88-specific 1H2 T-cell hybridoma. This demonstrates that ESX Ags delivered to the surface of conventional DCs, pDCs, or Mf via CD11b, CD11c, MHC-II, or BST-2 gain access to the MHC-II machinery.
In vivo delivery of Ag-SA to DC subsets allows Ag presentation
We evaluated the in vivo specificity of ESX Ag-SA delivery to DC subsets as well as internalization and efficiency of their presentation. For the initial in vivo assessment of the strategy, the intravenous (i.v.) model was chosen, which, unlike the lungs or dermis, offers the unique possibility to target distinct splenic DC subsets and does allow to obtain sufficient numbers of T cells for a detailed analysis of the induced responses. Mice were injected i.v. with 500 pmol ( ¼ 10 mg) per mouse of ESAT-6-SA, complexed to biot-anti-CD11b mAb or to biot-control IgG at a molar ratio of 2:1, together with 25 mg of the TLR3 agonist poly(cytidylic-inosinic) (poly I:C), a synthetic analog of double-stranded RNA, the adjuvant used in further immunizations. At different time points postinjection, spleen low-density cells were analyzed for the presence of ESAT-6-SA at the surface of DC subsets (Figure 2a ). ESAT-6-SA binding was detectable 3 h postinjection, only at the surface of CD11c
DCs. ESAT-6-SA was barely detectable at the surface of DCs 24 h postinjection, suggesting the internalization of the bound ESAT-6-SA. In parallel, CD11c-eYFP mice were injected with 500 pmol ( ¼ 10 mg) per mouse of ESAT-6-SA complexed to biot-anti-CD11c mAb or to biot-control IgG. Only CD11c-eYFP cells from the former stained positively for ESAT-6-SA at 6 h, and to a lesser extent at 24 h (Figure 2b) , showing the specificity of binding followed by the internalization of the delivered Ag.
We then studied the in vivo Ag presentation by the targeted DC after injection of Ag-SA:biot-mAb complexes. BALB/c mice were injected i. The potential of the ESX Ag delivery to DCs to trigger T-cell responses was then investigated in vivo with or without poly I:C as adjuvant, based on its well-established structural interaction with endosomal TLR3 or with cytosolic double-stranded RNA sensors, i.e., retinoic acid-inducible gene-I and melanoma differentiation-associated gene-5 RNA helicases, expressed by multiple cell types. 14 Poly I:C also induces type-I IFNs, necessary to induce Th1 and CTL responses. 15 DCs triggered via TLR3 also drive Th17 differentiation. 16 This immunization strategy was first assessed subsequent to a single injection. C57BL/6 mouse groups (n ¼ Delivery of ESAT-6 to CD207 induced weaker, but still marked IFN-g T-cell responses. ESAT-6 targeting to CD209 was not immunogenic, possibly due to the anti-inflammatory properties of CD209 ligation. 17 When CpG (TLR-9 agonist) was used as an adjuvant together with ESAT-6-SA and biotanti-CD11b mAb, Th1-but not Th17-responses were also induced, yet at a lesser extent compared with poly I:C (Supplementary Figure S4A,B online) .
Although the ESX-SA protein used at 1 mM in vitro induced some degrees of DC maturation (Supplementary Figure S2 online), in vivo immunization with 50 pmol per mouse of ESAT-6-SA delivered to CD11b, without an adjuvant, did not induce detectable T-cell responses (Figure 3a,b) , suggesting that, due to the weak amounts of ESX-SA required to stimulate immune responses in vivo, these recombinant proteins-or their possible contaminants-did not reach sufficient concentration in the microenvironment of the targeted DCs to induce their maturation.
In this framework, Ag delivery to pDCs via BST-2 was not feasible, as poly I:C, which induces the production of type I/II IFN, 18 induced BST-2 expression by a broad range of immune cells ( Figure 3c ) and loss of pDC specificity of BST-2 expression.
In conclusion, following a single immunization, Ag delivery to b 2 -integrins or to CD205 was as efficient for T-cell priming, while CD207 targeting induced less intense T-cell responses and CD209 targeting did not initiate T-cell response. extending the feasibility of the strategy to various ESX Ags and MHC haplotypes and genetic backgrounds.
We also evaluated T-cell responses after the administration of ESAT-6-SA complexed to biot-anti-CD11b mAb at different doses ranging from 250 to 5 pmol ( ¼ 5-0.1 mg) per mouse. The rational of CD11b targeting was its consistent efficiency in the previous experiments and the necessity to keep the targeted DC receptor constant to vary several other parameters. Only 50 pmol ( ¼ 1 mg) per mouse were enough to induce potent IFN-g, IL-2, and IL-17, but not IL-5 responses at their maximal intensities ( Figure 4c) . As little as 5 pmol ( ¼ 0.1 mg) per mouse of ESAT-6-SA were still able to trigger Th1 and Th17 responses, showing the efficiency of the Ag delivery approach.
Other features of the ESX Ag delivery
The hypothesis that the biot-mAbs operate in vivo via Fc receptors (FcRs) rather than their specific DC surface ligands was negated by the observation that ESAT-6-SA complexed to biot-control IgG did not induce T-cell responses (Figure 3a,b) . Moreover, FcRg 1/1 mice mounted lymphoproliferative and IFN-g (Figure 5a ,b) responses comparable to their wild-type counterparts after immunization with ESAT-6 delivery to CD11b. Treg-mediated control of effector T cells has to be taken into account in immunization strategies. 19, 20 Lymphoproliferative, IFN-g and IL-2 ( Figure 5c,d ) responses induced by ESAT-6-SA delivery to CD11b were controlled by Tregs, as shown by their increase in anti-CD25 mAb-treated, i.e., Treg-attenuated mice, compared with their Treg-sufficient counterparts, treated with a control Ig isotype.
Efficient boosting of BCG-induced T-cell responses by Ab-mediated delivery of ESX Ags to DCs
Priming with BCG followed by boosting with potent subunit vaccines is considered the most promising TB vaccination strategy. 8 We evaluated T-cell responses in BCG-primed mice boosted with ESX Ags delivered through different DC receptors. Given the increasing interest of C-type lectins in Ag delivery systems, 21 we choose these DC receptors as target. BALB/c mice, naïve or primed with 1 Â 10 6 colony-forming unit per mouse of BCG on day 0, were injected i.v. on days 14 and 21 with 50 pmol ( ¼ 1 mg) per mouse of TB10.4-SA complexed to different biot-mAbs. Two rounds of intranasal (i.n.) immunizations were performed based on the fact that numerous vaccination regimens require multiple injections. On day 28, notable CD4 þ T-cell IFN-g responses were detected in BCG-unprimed mice that were immunized with TB10.4 delivered to CD205, CD207, CD209, or DCIR-2, with the highest levels obtained with CD207 and DCIR-2 ( Figure 6a) . Such responses were comparably increased following boosting of BCG-primed mice with TB10.4-SA complexed to biot-mAbs specific to CD205, CD207, CD209, or DCIR-2, but not to the biot-control IgG.
Th17 responses were not detectable in BCG-unprimed BALB/c mice immunized with TB10.4-SA complexed to different biot-mAbs (Figure 6b) . In contrast, Th17 responses were induced in BCG-primed mice when TB10.4 was delivered to CD205 and, to a lesser extent, upon delivery through CD207, CD209, or DCIR-2. Determination of the reasons of the lack of Th17 responses in BCG-unprimed BALB/c mice immunized by TB10.4 delivery to CD205 and the presence of Th17 responses in C57BL/6 mice immunized by ESAT-6 delivery to CD205 (Figure 3b ) will require more investigation in these two models with comparable immunization regimens.
In mice immunized with TB10.4 delivered to CD205, the levels of TB10.3/4:20-28-specific CD8 þ T splenocytes were low but detectable (Figure 6c 
DCs induces TB protection
Having demonstrated the highly specific Ag delivery to splenic DC subsets and the efficiency of specific T-cell triggering upon i.v. immunization, we next transposed it to i.n. immunization to induce protective mucosal anti-mycobacterial immunity. In line with previous reports, 22 we observed that CD205 is specifically expressed by all lung CD11c þ cells, and its expression level remained constant following i.n. poly I:C treatment (Figure 7a) . Notably, the CD205 expression was not extended to other lung innate cells, i.e., CD11b
À , after poly I:C treatment (not shown). We therefore evaluated whether CD205 represents an appropriate target for Ag delivery to lung DCs. BALB/c mice were immunized on days 0 and 9 with i.n. injections of 600 pmol ( ¼ 15 mg) per mouse of TB10.4-SA complexed at a molar ratio of 4:1 to biotanti-CD205 mAb. This immunization resulted in TB10.4-specific CD4
þ T-cell IFN-g responses detectable at day 22 in the lungs (Figure 7b) .
To evaluate the protective potential of this immunization, BALB/c mice were vaccinated following the same regimen, whereas control individuals were immunized s.c. on day 0 with BCG as a ''gold standard'' vaccine control to which new TB vaccine candidates are systematically compared. 23 Mice were challenged with an aerosol of M. tuberculosis on day 22. At 1 month postinfection, a decreased mycobacterial burden was observed in the lungs from mice immunized with TB10.4 directed to airway CD205
þ DCs compared with lungs from mice unvaccinated or injected with TB10.4-SA complexed to biot-control IgG. In parallel, a substantial decrease of mycobacterial dissemination to the spleen was observed (Figure 7c ). In contrast, mice immunized by i.v. route with TB10.4-SA delivered to CD11b, CD205, or CD207 only displayed a weak protection and this did not reach statistical significance (Supplementary Figure S5 online ). This observation is in accordance with previous data showing that priming of mycobacteria-specific effector T cells in the local lung lymph nodes and their recruitment to the airway lumen at the time of pulmonary TB exposure are a more reliable correlate for protection than the presence of peripherally activated specific T cells. 24, 25 Thus, our results show that ESX Ag delivery to the lung CD205 þ DCs by the technology described herein represents a promising step forward in the design of novel TB vaccine candidates.
DISCUSSION
Immunization based on the delivery of immunogens to DC subsets may provide new insights into the type of adaptive protective immunity. However, as the mechanisms governing functions of DC subsets are not thoroughly understood, it remains difficult to predict which DC subsets are the most appropriate targets to optimize protective immunity. Here, to compare the impact of targeting the different DC subsets on mycobacteria-specific protective immunity, we developed a versatile approach allowing the delivery of mycobacterial immunogens to different DC surface receptors. Our approach consists of the genetic fusion of mycobacterial immunogens from the ESX family to SA. The resulting Ag-SA fusion tetramers can then form stable complexes with targeting biot-mAbs specific for a range of receptors on DC surfaces. The Ag-SA:biot-mAb complexes can then deliver these immunogens into DCs through endocytosis with the selected surface receptors, thus enabling Ag processing and presentation and leading to the induction of adaptive immunity. This approach allowed efficient delivery of ESX-SA to selected DC subsets through b 2 -integrins or C-type lectins. The ensuing efficient endocytosis of cell-bound Ag-SA:biot-mAb complexes was most likely due to the crosslinking of the targeted receptors by the biot-mAbs, leading to their capping together with the bound ESX-SA cargo. The ESX Ags were then processed and presented on MHC-II molecules to specific T-cell receptors in an efficient manner. This Ag delivery was highly specific; only the ex vivo sorted DC subset targeted with ESX-SA complexed to the selected biot-mAbs displayed the bound ESX on their surfaces and were able to trigger specific T cells. We further demonstrated the efficient induction of ESXspecific Th1, Th17, and CD8 þ T-cell responses when injected concomitantly with the adjuvant. [27] [28] [29] [30] and (ii) the notable T-cell responses following mAb-mediated OVA Ag targeting to CD11c. 31 Among the C-type lectins evaluated here, CD205 was the most efficient target receptor for Ag-SA delivery to DCs and induction of Th1 and Th17 cells in primary and booster immunizations against ESX Ags. This integral transmembrane mannose receptor is intensely expressed by cortical thymic epithelium and DC subsets, including lung DCs. 32 Moreover, compared with most other surface endocytic receptors, whose ligation induces endocytosis through early and more peripheral endosomes, CD205 is rapidly taken up after binding with carbohydrates, and its cytosolic domain mediates efficient endocytosis and recycling through the late endosomes and MHC-II-rich compartments. 33 Furthermore, in addition to its capacity to shuttle Ags from the extracellular space into specialized MHC-II rich lysosomal compartments, CD205 is also able to introduce Ags to the MHC-I processing machinery. These properties likely account for the observed efficiency of crosspriming of TB10.4-specific CD8 þ T-cell in BCG-primed mice that were boosted with TB10.4-SA targeted to CD205, but not other C-type lectins tested.
The significant efficiency of T-cell triggering following ESX-SA delivery to CD207 is in agreement with the significant T-cell responses subsequent to OVA Ag targeting through this C-type lectin. 34 Importantly, CD207 mRNA is detectable in the mouse lungs and in the epithelium lining human airways. 35 Directing of Ags for presentation by DCs through CD207 may thus be of interest for Ag delivery to lung DCs and induction of mucosal T cells close to the primary site of the mycobacterial infection.
In addition to the early production of IL-17 by lung T-cell receptor gd þ T cells, 36 CD4 þ Th17 cells can be detected in mycobacteria-exposed mice and humans. 37 However, the direct contribution of Th17 in the control of M. tuberculosis infection remains debatable. 38, 39 Mice immunized through delivery of ESX-SA to CD11b, CD11c, or CD205 developed significant Th17 responses. Notably, the DC receptor candidates that most significantly induced the Th17 responses also induced the highest Th1 responses. This is in accordance with the hypothesis that Th17 cells may facilitate the chemoattraction of Th1 cells. 40 The strategy developed here enabled the induction of lung mucosal Th1 responses and reproducible anti-mycobacterial protection when used in i.n. immunization with TB10.4 directed to airway CD205 þ DCs. These data provide proof of principle for directing mycobacterial Ags to airway DC subsets, which leads to the induction of mucosal immunity and protection against infection. Our results further demonstrate that the i.v. and i.n. routes of immunization differ in their ability to induce TB protection. Indeed, in accordance with previous data, 25 our study clearly shows that the presence of specific T cells at the primary site of the mycobacterial infection, subsequent to i.n. mucosal immunization, rather than a strong systemic T-cell response, is required for the control of mycobacterial infection. Considering that several human counterparts of mouse DC subtypes have been identified and that targeted Ag delivery to endocytic C-type lectins at DC surface allows efficient Ag presentation in human, this vaccination strategy leads to new advances that increases our insight of the development of new human TB vaccines. The use of recombinant ESX Ags either alone or in fusion with other mycobacterial immunogens, formulated in appropriate adjuvants, constitutes a promising TB subunit vaccine strategy. 41, 42 Our approach should not to be considered as competing with the other subunit TB vaccines under development. Rather, it represents a potent complementary strategy that can now be evaluated for direct delivery of newly described Ags or combination of protective early and latency-associated mycobacterial Ags 41 to lung DC and is expected to allow substantial reduction of the required dose of Ag and better control of the quality of the adaptive immunity.
METHODS ESX-SA fusion proteins and peptides. The construction and purification of the Ag-SA fusion proteins have been described recently. 12 Briefly, the open reading frames encoding ESX Ags ESAT-6, CFP-10, or TB10.4 were PCR-amplified with specific primers (Supplementary Table S1 online) and fused in frame to the 5 0 end of a codon-optimized synthetic gene encoding residues 13-139 of SA from Streptomyces. Sequence-confirmed Ag-SA fusion proteins were produced as soluble Ag-SA tetramers as described. 12 Lipopolysaccharide content in eluted proteins was reduced by passage through EndoTrap columns (Profos, Regensburg, Germany) to levels below 50 endotoxin unit (EU) of lipopolysaccharide per mg of protein, as determined by the Limulus Amebocyte Lysate assay (Lonza, Walkersville, MD).
The ESAT-6:1-20, CFP-10:11-25, TB10.4:74-88 peptides, containing MHC-II-restricted T-cell epitopes, and TB10.3/4:20-28 peptide, containing an MHC-I restricted T-cell epitope, were synthesized by NeoMPS (Strasbourg, France).
Biot-mAbs. mAbs specific to CD11b (M1/70.15.11.5.HL, rat IgG 2b ), CD11c (N418, hamster IgG), DCIR-2 (33D1, rat IgG 2b ), MHC-II (I-A/ I-E) (M5/114.15.2, rat IgG 2b ), or the control Ig (R187, rat IgG) were biotinylated as described. 12 Biot-anti-CD205 mAb (NLDC-145, rat IgG 2a ) was from Celldex Therapeutics (Needham, MA). Biot-mAbs specific to CD207 (eBioL31, rat IgG 2a ), CD209 (LWC06, rat IgG 2a ), or CD317 (BST-2) (eBio927, rat IgG 2b ) were from eBioscience (San Diego, CA). Absence of endotoxin in the IgG preparations was verified by the Limulus Amebocyte Lysate assay.
Detection of ESAT-6 binding to DC surface receptors. Conventional DCs or pDCs were generated as described 43 and were incubated at 1 Â 10 6 cells per well at 41C with 1.5 mg ml À 1 of biot-mAbs. Cells were then washed and incubated with 1 mM of ESAT-6-SA for 1 h at 41C. The presence of ESAT-6-SA on DC surfaces was detected by cytofluorometry using the anti-ESAT-6 mAb (11G4; Antibody Shop, Gentofte, Denmark) labeled with fluoprotein (FP) 647H (Interchim, Montluc¸on, France). Mean fluorescence intensity (MFI) reduction of the cell surface-bound ESAT-6-SA after endocytosis were calculated as 100 À ((MFI biot-mAb þ ESAT-6-SA 371C ) À (MFI biot-control IgG þ ESAT-6-SA 41C )/ (MFI biot-mAb þ ESAT-6-SA 41C ) À (MFI biot-control IgG þ ESAT-6-SA 41C )) Â 100.
In vivo binding of ESAT-6-SA to spleen DC subsets was studied after i.v. injection of ESAT-6-SA complexed with the biot-mAbs together with poly I:C. Low-density splenocytes 44 were stained with a combination of DC-specific and FP 647H -anti-ESAT-6 mAbs for cytoflurometric analysis. Mice and immunization. Female BALB/c, C57BL/6, or C3H mice (Charles Rivers, Arbresle, France) were immunized at 6-12 weeks old. Ag-SA and biot-mAbs were complexed at the indicated doses at 41C for 1 h and were injected i.v. at 200 ml per mouse. BCG (Pasteur 1173P2) was injected s.c. at the base of the tail. C57BL/6 FcgR 1/1 mice, deficient for the activating FcgRI, III, and IV were provided by Pierre Bruhns and Marc Daeron (Institut Pasteur, Paris, France). C57BL/6 CD11c-eYFP mice were provided by Orchidée Filipe-Santos and Philippe Bousso (Institut Pasteur). Treg attenuation was performed by an intraperitoneal injection of 1 mg per mouse of anti-CD25 mAb (PC61) or control IgG at 2 days before immunization. Animal studies were approved by the Institut Pasteur Safety Committee, the National Ethics Committee, in accordance with the European guidelines.
T-cell assays. CD4 þ T-cell assays were performed on splenocytes stimulated in vitro with various concentrations of synthetic peptides containing MHC-II-restricted epitopes. Culture supernatants were assessed at 24 h for the presence of IL-2 and at 72 h for IL-5, IFN-g, and IL-17A as described. 47 
CD8
þ T-cell responses were evaluated in splenocytes, stimulated in vitro with 10 mg ml À 1 of TB10.3/4:20-28 peptide. 48 At day 6, specific CD8
þ T lymphocytes were detected by a phycoerythrinconjugated pentamer of H-2K d complexed to TB10.3/4:20-28 (Proimmune, Oxford, UK) in the presence of FITC-anti-CD8 a (53-6.7) and allophycocyanin-anti-CD44 (Ly-24) (IM7) mAbs from BD/PharMingen (Le Pont de Claix, France). Cells were acquired on a Cyan cytometer (Beckman Coulter, Grenoble, France) and analyzed by FlowJo program (Treestar, OR).
